JOHNSON & JOHNSON (JNJ) — SEC Filings

Latest SEC filings for JOHNSON & JOHNSON (JNJ), explained in plain English.

Sentiment Overview: 2 bullish, 47 neutral

Recent Filings (49)

• 13F-HR Filing — 13F-HR · 2025-11-13T00:00:00.000Z [neutral]
• J&J Q3 Earnings Soar 91% on Strong Sales, R&D Efficiency — 10-Q · 2025-10-22T00:00:00.000Z [bullish] Risk: medium
  Johnson & Johnson reported robust financial performance for the fiscal third quarter ended September 28, 2025, with sales to customers increasing by 6.77% to $2
• J&J Reports Financials, Details Debt Issuances — 8-K · 2025-10-14T00:00:00.000Z [neutral] Risk: low
  Johnson & Johnson filed an 8-K on October 14, 2025, reporting on its financial condition and other events. The filing details various debt issuances, including
• J&J Board Changes and Executive Compensation Details — 8-K · 2025-09-09T00:00:00.000Z [neutral] Risk: low
  Johnson & Johnson announced on September 8, 2025, changes in its board of directors and executive compensation. Specifically, the company reported the departure
• J&J Navigates Debt Landscape, Manages Shareholder Equity in Q2 — 10-Q · 2025-07-24T00:00:00.000Z [neutral] Risk: low
  Johnson & Johnson (JNJ) reported its Q2 2025 results for the period ending June 29, 2025. The company's financial statements indicate a stable capital structure
• 13F-HR Filing — 13F-HR · 2025-07-22T00:00:00.000Z [neutral]
• J&J Files 8-K on Financials and Debt Offerings — 8-K · 2025-07-16T00:00:00.000Z [neutral] Risk: low
  Johnson & Johnson filed an 8-K on July 16, 2025, reporting on its results of operations and financial condition. The filing includes various exhibits related to
• J&J Reports Director Changes and Debt Issuances — 8-K · 2025-06-10T00:00:00.000Z [neutral] Risk: low
  Johnson & Johnson filed an 8-K on June 10, 2025, reporting on the departure of directors, election of new directors, appointment of officers, and compensatory a
• 13F-HR Filing — 13F-HR · 2025-05-07T00:00:00.000Z [neutral]
• J&J Files 8-K: Director Changes, Officer Comp, Shareholder Votes — 8-K · 2025-04-30T00:00:00.000Z [neutral] Risk: low
  Johnson & Johnson filed an 8-K on April 30, 2025, reporting on the departure of directors, election of new directors, and compensatory arrangements for officers
• J&J 10-Q: Debt Maturities and Financial Snapshot — 10-Q · 2025-04-23T00:00:00.000Z [neutral] Risk: low
  Johnson & Johnson filed its 10-Q for the period ending March 30, 2025. The filing details the company's financial position, including various debt instruments s
• J&J Files 8-K Detailing Financials and Notes — 8-K · 2025-04-15T00:00:00.000Z [neutral] Risk: low
  Johnson & Johnson filed an 8-K on April 15, 2025, reporting on its Results of Operations and Financial Condition, as well as other events and financial statemen
• J&J Files 8-K Detailing Debt Maturities — 8-K · 2025-04-03T00:00:00.000Z [neutral] Risk: low
  Johnson & Johnson filed an 8-K on April 3, 2025, reporting on its financial statements and exhibits as of March 31, 2025. The filing details various notes with
• J&J Executive Compensation Details Revealed — DEF 14A · 2025-03-12T00:00:00.000Z [neutral] Risk: low
  Johnson & Johnson filed its DEF 14A on March 12, 2025, detailing executive compensation for the fiscal year ending December 29, 2024. The filing includes inform
• J&J Files 8-K on Multiple Debt Offerings — 8-K · 2025-02-26T00:00:00.000Z [neutral] Risk: low
  On February 26, 2025, Johnson & Johnson filed an 8-K report detailing various debt issuances. These include $1.150 billion in notes due November 2028, $3.20 bil
• J&J Files 8-K on Debt Issuances — 8-K · 2025-02-20T00:00:00.000Z [neutral] Risk: low
  On February 20, 2025, Johnson & Johnson filed an 8-K report detailing various debt issuances. These include notes due in November 2028, November 2032, 2035, Nov
• 13F-HR Filing — 13F-HR · 2025-02-13T00:00:00.000Z [neutral]
• Johnson & Johnson Files 2024 10-K — 10-K · 2025-02-13T00:00:00.000Z [neutral] Risk: medium
  Johnson & Johnson filed its 2024 10-K report on February 13, 2025, detailing its fiscal year ending December 29, 2024. The company, headquartered in New Brunswi
• J&J Files 8-K/A Amendment with Debt Details — 8-K/A · 2025-01-22T00:00:00.000Z [neutral] Risk: low
  Johnson & Johnson filed an 8-K/A amendment on January 22, 2025, to report financial statements and exhibits. This filing specifically includes details about var
• 13F-HR Filing — 13F-HR · 2024-11-13T00:00:00.000Z [neutral]
• SC 13G/A Filing — SC 13G/A · 2024-11-01T00:00:00.000Z [neutral]
• Johnson & Johnson Q3 2024 10-Q Filing — 10-Q · 2024-10-23T00:00:00.000Z [neutral] Risk: low
  Johnson & Johnson filed its 10-Q for the period ending September 29, 2024. The filing details financial performance and operational updates for the third quarte
• SC 13G/A Filing — SC 13G/A · 2024-10-18T00:00:00.000Z [neutral]
• Johnson & Johnson Files 8-K with Financial Updates — 8-K · 2024-10-15T00:00:00.000Z [neutral] Risk: low
  On October 15, 2024, Johnson & Johnson filed an 8-K report detailing financial information. The filing includes details on various notes due in different years,
• J&J Files 8-K on Debt Issuances — 8-K · 2024-09-20T00:00:00.000Z [neutral] Risk: low
  On September 20, 2024, Johnson & Johnson filed an 8-K report detailing various debt issuances. These include notes due in 2024, 2028, 2032, 2035, 2036, and 2044
• J&J Board Changes and Officer Compensation Updates — 8-K · 2024-09-10T00:00:00.000Z [neutral] Risk: low
  On September 10, 2024, Johnson & Johnson filed an 8-K report detailing changes in its board of directors and executive compensation. Specifically, the filing an
• J&J Executive Shuffle: New CFO, Medical Devices Chair Departs — 8-K · 2024-08-26T00:00:00.000Z [neutral] Risk: medium
  Johnson & Johnson announced on August 26, 2024, changes in its executive leadership, including the appointment of Thong Q. Nguyen as Executive Vice President, C
• 13F-HR Filing — 13F-HR · 2024-08-09T00:00:00.000Z [neutral]
• SC 13G Filing — SC 13G · 2024-07-30T00:00:00.000Z [neutral]
• Johnson & Johnson Q2 2024 10-Q Filed — 10-Q · 2024-07-25T00:00:00.000Z [neutral] Risk: low
  Johnson & Johnson filed its 10-Q for the period ending June 30, 2024. The company's fiscal year ends on December 29th. Key financial data and debt instruments,
• J&J Files 8-K on Financials and Debt — 8-K · 2024-07-17T00:00:00.000Z [neutral] Risk: low
  On July 17, 2024, Johnson & Johnson filed an 8-K report detailing its financial condition and results of operations. The filing includes information on various
• J&J Issues $5B in Notes — 8-K · 2024-05-20T00:00:00.000Z [neutral] Risk: low
  On May 20, 2024, Johnson & Johnson filed an 8-K report detailing the issuance of $5.0 billion aggregate principal amount of senior unsecured notes. The notes ar
• SC 13G/A Filing — SC 13G/A · 2024-05-20T00:00:00.000Z [neutral]
• J&J Prices $15B in Senior Notes — 8-K · 2024-05-17T00:00:00.000Z [neutral] Risk: low
  On May 17, 2024, Johnson & Johnson filed an 8-K report detailing the issuance of new debt. The company announced the pricing of $15 billion aggregate principal
• 13F-HR Filing — 13F-HR · 2024-05-10T00:00:00.000Z [neutral]
• Johnson & Johnson Files Q1 2024 10-Q — 10-Q · 2024-05-01T00:00:00.000Z [neutral] Risk: low
  Johnson & Johnson filed its 10-Q for the period ending March 31, 2024. The company reported its financial results for the first quarter of 2024. Key financial d
• J&J Issues New Debt, Files Financials — 8-K · 2024-04-29T00:00:00.000Z [neutral] Risk: low
  On April 25, 2024, Johnson & Johnson filed an 8-K report detailing the issuance of new debt securities. This includes $5.50 billion in notes due in 2024, $1.65
• J&J Files 8-K/A Amendment on Debt and Stock — 8-K/A · 2024-04-16T00:00:00.000Z [neutral] Risk: low
  Johnson & Johnson filed an 8-K/A on April 16, 2024, to amend a previous filing. The amendment pertains to financial statements and exhibits, specifically noting
• SC 13G Filing — SC 13G · 2024-04-10T00:00:00.000Z [neutral]
• J&J Executive Compensation Details Revealed — DEF 14A · 2024-03-13T00:00:00.000Z [neutral] Risk: low
  Johnson & Johnson filed a DEF 14A on March 13, 2024, detailing executive compensation for the fiscal year ending December 31, 2023. The filing includes informat
• J&J Files 2023 10-K, Details Debt Maturities — 10-K · 2024-02-16T00:00:00.000Z [neutral] Risk: low
  Johnson & Johnson (JNJ) filed its 10-K on February 16, 2024, for the fiscal year ended December 31, 2023. The filing details various financial instruments, incl
• 13F-HR Filing — 13F-HR · 2024-02-14T00:00:00.000Z [neutral]
• SC 13G/A Filing — SC 13G/A · 2024-02-13T00:00:00.000Z [neutral]
• J&J Reports 2.4% Stake in Nanobiotix S.A. as of Dec 31, 2023 — SC 13G/A · 2024-02-02T00:00:00.000Z [neutral]
  Johnson & Johnson (J&J) filed an amended SC 13G/A on February 2, 2024, disclosing its ownership in Nanobiotix S.A. as of December 31, 2023. J&J, a pharmaceutica
• State Street Corp. Amends J&J Stake Filing as of Dec 31, 2023 — SC 13G/A · 2024-01-30T00:00:00.000Z [neutral]
  State Street Corporation, a major financial institution, filed an amended SC 13G/A on January 30, 2024, disclosing its ownership of Johnson & Johnson common sto
• BlackRock Amends J&J Stake: Passive Ownership Update — SC 13G/A · 2024-01-26T00:00:00.000Z [neutral]
  BlackRock Inc. filed an amended SC 13G/A on January 26, 2024, disclosing its ownership of Johnson & Johnson common stock as of December 31, 2023. This filing, A
• J&J Discloses 182.3M Kenvue Shares Post-Spin-Off — SC 13G · 2024-01-24T00:00:00.000Z [neutral]
  Johnson & Johnson (J&J) filed an SC 13G on January 24, 2024, disclosing its beneficial ownership of 182,329,550 shares of Kenvue Inc. common stock as of Decembe
• J&J Files 8-K on Operations & Financial Condition, Details Notes Due — 8-K · 2024-01-23T00:00:00.000Z [neutral]
  Johnson & Johnson (JNJ) filed an 8-K on January 23, 2024, to report its results of operations and financial condition. The filing specifically mentions several
• J&J to Acquire Ambrx, Boosting Oncology Pipeline with Next-Gen ADCs — DEFA14A · 2024-01-08T00:00:00.000Z [bullish]
  Johnson & Johnson (JNJ) announced on January 8, 2024, its definitive agreement to acquire Ambrx Biopharma, Inc. (AMAM), a clinical-stage biopharmaceutical compa